Fed Pullback Pledge...
Health Care: Drugs
Supernus Pharmaceuticals Inc (SUPN: NASDAQ)
$6.71 0.04 | 0.60%
06/19/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 6.67 |
| 52 Week High | 16.68 |
| 52 Week Low | 4.45 |
| Avg. Daily Vol. (Mil) | 0.59 |
| Beta (3 year) | 0.00 |
| Share Related Items | |
| Mkt Cap (Mil) | 206.67 |
| Shares Out (Mil) | 30.99 |
| Float (Mil) | 10.14 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.70 |
| Current Ratio | 2.80 |
| LT Debt/ Equity | 0.19 |
| Total Debt / Equity | 0.49 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 145.75 |
| Price/Book | 5.01 |
| Price/Cash Flow | -3.80 |
| Per Share Data | |
| Earnings | -2.12 |
| Sales | 0.05 |
| Book Value | 1.33 |
| Cash Flow | -1.76 |
| Business Summary | |
|---|---|
| Supernus Pharmaceuticals Inc., specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. | |
| General Information | |
| 1550 East Gude Drive
Rockville, MD 20850 |
|
| www.supernus.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 193 | |
| CEO: Jack Khattar | |
| Short Interest | |
| Current Month (Mil) | 3.26 |
| Previous Month (Mil) | 3.70 |
| Short Interest Ratio (Days) | 3.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -70.10 |
| Return on Investments | -112.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with SUPN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- UserPharma
- ContributorStocks Under-$10 Moving Hig...
Latest SUPN Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar 06.13.13 | 02:06 pm
- Commit To Purchase Supernus Pharmaceuticals At $5, Earn 17% Annualized 06.11.13 | 02:06 pm
- Supernus Receives Tentative Approval For Trokendi XR(TM) 06.10.13 | 09:06 am
- Supernus To Present At Two Investor Conferences 05.20.13 | 04:05 pm
- 5 Stocks Setting Up to Break Out 05.17.13 | 01:05 pm
- 8 Stocks Under $10 Trending Sharply Higher 05.14.13 | 11:05 pm
- Supernus Pharmaceuticals Reports First Quarter 2013 Financial Results 05.13.13 | 04:05 pm
- Supernus Announces First Quarter 2013 Earnings Conference Call And Webcast 05.06.13 | 04:05 pm
- Supernus Announces Closing Of $90 Million Of 7.50% Convertible Senior Secured Notes Due 2019 05.06.13 | 08:05 am
- Supernus Prices Offering Of $75 Million Of 7.50% Convertible Senior Secured Notes Due 2019 04.26.13 | 09:04 am
Press Releases for SUPN
Partner Headlines for SUPN
- UPDATE: Citigroup Initiates Supernus Pharmaceuticals at Neutral; Fully Valued - Benzinga 11.27.12 | 01:11 pm
- Pipeline Advances at Supernus - Analyst Blog - Zacks 11.26.12 | 07:11 pm
- Apollo Group SPIKES 10% to Lead These 5 NASDAQ Top Percentage Winners - Wall St. Cheat Sheet 06.27.12 | 10:06 am
- SBA Enters MERGER Agreement and Other Stocks that Have Hit 52-Week Highs - Wall St. Cheat Sheet 06.27.12 | 10:06 am
- Morning Market Movers - Benzinga 06.26.12 | 09:06 am
